Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:08 AM
Ignite Modification Date:
2025-12-25 @ 3:08 AM
NCT ID:
NCT00000105
Eligibility Criteria:
Inclusion Criteria:
* Patients must have a diagnosis of cancer of any histologic type.
* Patients must have a Karnofsky performance status great or equal to 70%.
* Patients must have an expected survival for at least four months.
* Normal healthy volunteers to serve as control for this study.
* All patients must sign informed consent approved by the Committee on the Use of Human Subjects at the University of Minnesota
Exclusion Criteria:
* Pregnant or lactating women. Females of child-bearing potential will be asked to take a pregnancy test before receiving vaccines.
* Serious intercurrent medical illnesses which would interfere with the ability of the patient to carry out the follow-up monitoring program.
* Immunization should not be administered during the course of any febrile illness or acute infection.
* Hypersensitivity to any component of the vaccine, including Thimerosal, a mercury derivative.
* The occurrence of any type of neurologic symptoms to tetanus vaccine in th past.
* Patients with a history of seafood allergy are excluded from receiving KLH.
* Subjects who have had tetanus toxoid within the last 7 years are not eligible for tetanus vaccine component of this protocol.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00000105
Study Brief:
Protocol Section:
NCT00000105